Patents by Inventor Ryan Rountree

Ryan Rountree has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY
    Publication number: 20240336595
    Abstract: This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway with little or no IMiD activity. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: July 13, 2022
    Publication date: October 10, 2024
    Inventors: Cristiana Guiducci, Mark Noviski, Janine Powers, Ryan Rountree, Ying Siow Tan
  • Cassette encoding a FPV/brachyury fusion protein
    Patent number: 11753652
    Abstract: The present invention relates to one or more promoters and/or expression cassettes that can be used for enhancing expression of a heterologous gene, such as Brachury. In particular, the one or more promoters and/or expression cassettes enhance expression of heterologous genes as part of a viral vector, such as a poxvirus.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 12, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Zengji Li, Alain Delcayre, Ryan Rountree
  • Compositions and methods for enhancing the stability of transgenes in poxviruses
    Patent number: 11654189
    Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
    Type: Grant
    Filed: July 5, 2021
    Date of Patent: May 23, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
  • Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses
    Publication number: 20210338788
    Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
    Type: Application
    Filed: July 5, 2021
    Publication date: November 4, 2021
    Applicant: Bavarian Nordic A/S
    Inventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
    Publication number: 20210205429
    Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 8, 2021
    Applicant: Bavarian Nordic A/S
    Inventors: Susan Foy, Stefanie Mandl, Ryan Rountree, Alain Delcayre
  • Compositions and methods for enhancing the stability of transgenes in poxviruses
    Patent number: 11052139
    Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 6, 2021
    Assignee: Bavarian Nordic A/S
    Inventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
  • Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses
    Publication number: 20200061174
    Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
    Type: Application
    Filed: September 28, 2017
    Publication date: February 27, 2020
    Applicant: Bavarian Nordic A/S
    Inventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
  • PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES
    Publication number: 20180216134
    Abstract: The present invention relates to one or more promoters and/or expression cassettes that can be used for enhancing expression of a heterologous gene, such as Brachury. In particular, the one or more promoters and/or expression cassettes enhance expression of heterologous genes as part of a viral vector, such as a poxvirus.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: Bavarian Nordic A/S
    Inventors: Zengji Li, Alain Delcayre, Ryan Rountree
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20150283220
    Abstract: Provided herein are vaccine compositions having potent adjuvant activity. Such compositions are capable of increasing anti-gen-specific antibody responses and increased frequency of Her-2-specific CD4+ T-cells, have improved anti-tumor efficacy, and are useful in methods of treating cancer.
    Type: Application
    Filed: October 16, 2013
    Publication date: October 8, 2015
    Applicant: Bavarian Nordic, Inc.
    Inventors: Stefanie Mandl, Ryan Rountree, Alain Delcayre